Display Settings:

Format

Send to:

Choose Destination
    Curr Opin Investig Drugs. 2007 Sep;8(9):758-68.

    Dabigatran etexilate, a thrombin inhibitor for the prevention of venous thromboembolism and stroke.

    Source

    Health Sciences University of Hokkaido, Department of Internal Medicine, 1757-Kanazawa, Ishikari-Tobetsu, Hokkaido 061-0293, Japan. iekom@hoku-iryo-u.ac.jp

    Abstract

    Dabigatran etexilate (BIBR-1048, Rendix), an orally active prodrug of the thrombin inhibitor dabigatran (BIBR-953ZW), is being developed by Boehringer Ingelheim Corp as a potential antithrombotic agent. By March 2003, the compound was in phase IIb/III trials for the prevention of deep vein thrombosis. By November 2005, a phase III trial had been initiated for the prevention of stroke and embolism due to atrial fibrillation and in May 2006 phase III trials for the prevention of secondary venous thromboembolism began. By July 2007, an EU filing for the drug had been made.

    PMID:
    17729188
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk